Avadel’s stock falls 21% after disclosing new FDA request for experimental narcolepsy drug


Shares of Avadel Pharmaceuticals PLC AVDL, +133.64% tumbled 21.6% in premarket trading on Thursday after the company said in a securities filing that the Food and Drug Administration requested additional information for its experimental narcolepsy drug. Avadel said it now expects to get a FDA decision on the drug, FT218, by June of next year. The company’s stock is down 58.1% this year, while the S&P 500 SPX, +2.47% has declined 16.5%.

This article was originally published by Marketwatch.com. Read the original article here.

Previous articleOutside the Box: Follow these 3 crucial lessons for weathering the stock market’s storm
Next articleThe Moneyist: ‘I’m a man of simple pleasures’: I live with my girlfriend, 59, who owns several homes and has saved $3 million. I pay utilities and cable, and do repairs. Is that enough?


Please enter your comment!
Please enter your name here